How to estimate market shares?
Let’s start with the hypothesis that your innovation will take a 60% market share. What does this percentage mean from your point of view? The estimation you provide will probably be correct. And posing this question to an audience familiar with marketing and sales will probably, again, elicit the correct answers. But comparing all the […]
Indirect Medical Costs
HTA bodies should take indirect (medical) costs into account to assess the cost/benefit-ratio of life sciences innovations HTA bodies may request the inclusion of indirect medical costs when 2 therapeutic options are compared by means of a health economic assessment. The methodology to include indirect medical costs differs from the classic inputs in a health […]
Managed Entry Agreements: Valuable or not?
Investing in ‘uncertainty’? Every innovative medical product on the market is subject to uncertainty. Uncertainty can be situated at the level of the volume (units / patients / events / ..) as well as at the level of medical and societal value and expectations (efficacy / safety / … ). Imagine you are the payor […]
Quality of Life – be vigilant!
Δ = innovation – SoC In general, in the world of market access of health care products, quality of life (QoL) is expressed in ‘utilities’. The healthier you are, the higher your utility score is. When performing health economic assessments, the difference in utilities for patients (delta utility) between the situation without and the situation […]
How to extrapolate a limited data set?
Each health economic analysis starts with clinical data. The trick is to reliably estimate the expected outcome using a limited dataset. In other words, if your sample (clinical study) does not provide mature data (interim data, small number of patients, large variance in results, …), how can you use this data as reliably as possible? […]
How to manage the costs of adverse events in a CE analysis?
Have you already performed health economic analyses? Then you will definitely recognise the following. To what level is it relevant to include costs in the analysis? For quite a few parameters, it is clear that they can have a decisive influence on your analysis and in your decision-making process. However, sometimes the effort you have […]
Clinical data, the key to a good market access dossier
The chicken or the egg. It’s a question that keeps many busy. The budget can be synonymous with the chicken and innovations synonymous with the egg (or the other way around, of course …). Anyway, any kind of innovation results in shifts in resources (lower consumption, higher efficacy, fewer side effects). For pharmaceuticals, it is […]
How to measure the value of innovation?
How to measure health benefits? Within healthcare, there is continuous innovation. New technologies are made available and (partly) replace existing resources or care. But how can you measure the financial value of innovation? It is not because a diagnostic device has 10 x sharper imaging that also a ten-fold health gain will be achieved, let […]